Reported about 15 hours ago
Eli Lilly and Company will acquire Verve Therapeutics for up to $1.3 billion, reflecting a 113% premium over Verve's recent share price. The deal, which could pay $10.50 per share in cash plus additional contingencies, is set to enhance Lilly's cardiometabolic pipeline with single-dose gene-editing therapies targeting cardiovascular diseases. Completion is expected by Q3 2025.
Source: YAHOO